Foreign Office Issues Caution as Valneva's Shares Keep Climbing
In the realm of vaccine development, Valneva continues to make strides, with its latest news focusing on its Lyme disease symptoms vaccine candidate, VLA15.
Recent data has shown strong results for VLA15, offering hope for those at risk of Lyme disease. This promising vaccine candidate is part of Valneva's growing portfolio, which also includes the Chikungunya vaccine, Ixchiq.
Ixchiq, an inactivated vaccine developed in partnership with Bavaria Nordic, is already available for certain groups. However, its journey has not been without challenges. There was a temporary suspension of Ixchiq in the US due to severe side effects reported among those over 65. Fortunately, these restrictions have since been lifted.
Valneva's stock price has reflected the positive momentum, with a more than five percent increase today, reaching 4.49 euros. This surge follows a recent purchase of Valneva stock by DER AKTIONÄR at a favourable price of 3.75 euros.
It's important to note that the CEO and majority owner of Börsenmedien AG, Bernd Förtsch, has been involved in a conflict of interest regarding the reporting on Valneva.
Looking ahead, a decision on the approval of VLA15 is expected in 2027. As Valneva continues to advance in the vaccine market, its commitment to developing effective and safe vaccines remains unwavering.
Read also:
- Connection Between ADHD and Trauma?
- West Nile Virus detected in Kentucky for the first time; authorities advise locals to adopt safety measures
- Authorities approve the euthanasia of a young woman from Barcelona, as requested by her father, halting the legal proceedings.
- Expansion of the care network is underway
